Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.

DeBuysscher BL, Scott D, Marzi A, Prescott J, Feldmann H.

Vaccine. 2014 May 7;32(22):2637-44. doi: 10.1016/j.vaccine.2014.02.087. Epub 2014 Mar 12.

2.

Rhabdovirus-based vaccine platforms against henipaviruses.

Kurup D, Wirblich C, Feldmann H, Marzi A, Schnell MJ.

J Virol. 2015 Jan;89(1):144-54. doi: 10.1128/JVI.02308-14. Epub 2014 Oct 15.

3.

Single injection recombinant vesicular stomatitis virus vaccines protect ferrets against lethal Nipah virus disease.

Mire CE, Versteeg KM, Cross RW, Agans KN, Fenton KA, Whitt MA, Geisbert TW.

Virol J. 2013 Dec 13;10:353. doi: 10.1186/1743-422X-10-353.

4.

Recombinant measles virus vaccine expressing the Nipah virus glycoprotein protects against lethal Nipah virus challenge.

Yoneda M, Georges-Courbot MC, Ikeda F, Ishii M, Nagata N, Jacquot F, Raoul H, Sato H, Kai C.

PLoS One. 2013;8(3):e58414. doi: 10.1371/journal.pone.0058414. Epub 2013 Mar 14.

5.

Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease.

Prescott J, DeBuysscher BL, Feldmann F, Gardner DJ, Haddock E, Martellaro C, Scott D, Feldmann H.

Vaccine. 2015 Jun 4;33(24):2823-9. doi: 10.1016/j.vaccine.2015.03.089. Epub 2015 Apr 10.

6.

Single-dose replication-defective VSV-based Nipah virus vaccines provide protection from lethal challenge in Syrian hamsters.

Lo MK, Bird BH, Chattopadhyay A, Drew CP, Martin BE, Coleman JD, Rose JK, Nichol ST, Spiropoulou CF.

Antiviral Res. 2014 Jan;101:26-9. doi: 10.1016/j.antiviral.2013.10.012. Epub 2013 Oct 30.

7.

Nipah virus: vaccination and passive protection studies in a hamster model.

Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, Chua KB, Lam SK, Buckland R, Deubel V, Wild TF.

J Virol. 2004 Jan;78(2):834-40.

8.

Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.

Brown KS, Safronetz D, Marzi A, Ebihara H, Feldmann H.

J Virol. 2011 Dec;85(23):12781-91. doi: 10.1128/JVI.00794-11. Epub 2011 Sep 14.

9.

Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months.

Pallister JA, Klein R, Arkinstall R, Haining J, Long F, White JR, Payne J, Feng YR, Wang LF, Broder CC, Middleton D.

Virol J. 2013 Jul 16;10:237. doi: 10.1186/1743-422X-10-237.

10.

Antibody prophylaxis and therapy against Nipah virus infection in hamsters.

Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, Deubel V, Buckland R, Wild TF.

J Virol. 2006 Feb;80(4):1972-8.

11.

Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs.

Kong D, Wen Z, Su H, Ge J, Chen W, Wang X, Wu C, Yang C, Chen H, Bu Z.

Virology. 2012 Oct 25;432(2):327-35. doi: 10.1016/j.virol.2012.06.001. Epub 2012 Jun 21.

12.

[Study on the DNA immunogenicity of fusion and attachment glycoproteins of Nipah virus].

Wang XJ, Ge JY, Wang QH, Hu S, Lin XM, Bu ZG.

Bing Du Xue Bao. 2008 Jan;24(1):47-52. Chinese.

PMID:
18320822
13.

Recombinant nipah virus vaccines protect pigs against challenge.

Weingartl HM, Berhane Y, Caswell JL, Loosmore S, Audonnet JC, Roth JA, Czub M.

J Virol. 2006 Aug;80(16):7929-38.

14.

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.

Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, Brining D, Scott DP, Geisbert TW, Kawaoka Y, Katze MG, Feldmann H, Messaoudi I.

Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14.

15.

A neutralization test for specific detection of Nipah virus antibodies using pseudotyped vesicular stomatitis virus expressing green fluorescent protein.

Kaku Y, Noguchi A, Marsh GA, McEachern JA, Okutani A, Hotta K, Bazartseren B, Fukushi S, Broder CC, Yamada A, Inoue S, Wang LF.

J Virol Methods. 2009 Sep;160(1-2):7-13. doi: 10.1016/j.jviromet.2009.04.037. Epub 2009 May 9.

PMID:
19433112
16.

Interactions of human complement with virus particles containing the Nipah virus glycoproteins.

Johnson JB, Aguilar HC, Lee B, Parks GD.

J Virol. 2011 Jun;85(12):5940-8. doi: 10.1128/JVI.00193-11. Epub 2011 Mar 30.

17.

Protection against henipavirus infection by use of recombinant adeno-associated virus-vector vaccines.

Ploquin A, Szécsi J, Mathieu C, Guillaume V, Barateau V, Ong KC, Wong KT, Cosset FL, Horvat B, Salvetti A.

J Infect Dis. 2013 Feb 1;207(3):469-78. doi: 10.1093/infdis/jis699. Epub 2012 Nov 21.

18.

Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.

Chattopadhyay A, Rose JK.

J Virol. 2011 Mar;85(5):2004-11. doi: 10.1128/JVI.01852-10. Epub 2010 Dec 22.

19.

Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Braxton CL, Puckett SH, Mizel SB, Lyles DS.

J Virol. 2010 Apr;84(7):3552-61. doi: 10.1128/JVI.01572-09. Epub 2010 Jan 20.

20.

Comparison of the pathogenicity of Nipah virus isolates from Bangladesh and Malaysia in the Syrian hamster.

DeBuysscher BL, de Wit E, Munster VJ, Scott D, Feldmann H, Prescott J.

PLoS Negl Trop Dis. 2013;7(1):e2024. doi: 10.1371/journal.pntd.0002024. Epub 2013 Jan 17.

Items per page

Supplemental Content

Write to the Help Desk